Kallistem
Entity

  • Kallistem

    Created in 2012
  • BETA

    Up & running (A)
    Existing signals show a regular activity

  • Social networks

    218

  • Activities

    deeptech biotech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    1 Av. Bourgelat, 69280 Marcy-l'Étoile, France

    Marcy-l'Étoile

    France

  • Employees

    Scale: 2-10

    Estimated: 3

  • SIREN

    751233792

  • Engaged corporates

    0
    0 0

  • Added in Motherbase

    3 years, 8 months ago
Description
  • Value proposition

    Kallistem is a biotech company specialized in spermatogenesis. The company was founded in 2012 with the objective to anticipate and treat male infertility. It promotes a technology and expertise developed by Philippe Durand and Marie-Helene Perrard, two internationally renowned scientists in the field of the reproductive biology and more specially in in vitro spermatogenesis.

    Kallistem has developed, in collaboration with its partners, original and innovating technologies of germinal cell culture for male fertility preservation and the treatment of male infertility.

    male fertility, cellular therapy, biology of reproduction, and testicular toxicology

  • Kallistem- Preservation of male fertility and treatment of male infertility

    <p>Kallistem is a biotech company specialized in spermatogenesis and in testicular toxicity in vitro. Originating from the Institute of Functional Genomics of Lyon (ENS Lyon), their research in the past 17 years aimed to develop and validate an innovative technology, Bio-AlteR®. This innovatide mdel is a unic technology for predicitve toxicology dedicated to testicular toxicity.</p>

    • https://www.kallistem.com/
Corporate interactions BETA
Corporate TypeTweets Articles
No interactions
Similar entities
Last news
Show all articles
Social network dynamics